Mucosal immunization with recombinant fusion protein DnaJ-ΔA146Ply enhances cross-protective immunity against Streptococcus pneumoniae infection in mice via interleukin 17A

Infection and Immunity

Volumn 82, Issue 4, 2014, Pages 1666-1675

  Liu, Yusi ^a   Wang, Hong ^a   Zhang, Shuai ^a   Zeng, Lingbin ^a   Xu, Xiuyu ^a   Wu, Kaifeng ^a   Wang, Wei ^a   Yin, Nanlin ^a   Song, Zhixin ^a   Zhang, Xuemei ^a   Yin, Yibing ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DNAJ A146PLY FUSION PROTEIN; GAMMA INTERFERON; HYBRID PROTEIN; IMMUNOGLOBULIN G; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 4; PNEUMOCOCCUS VACCINE; SECRETORY IMMUNOGLOBULIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL LOAD; BACTERIAL STRAIN; CELL INFILTRATION; CONTROLLED STUDY; CROSS PROTECTION; CYTOKINE PRODUCTION; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNIZATION; INFECTION PREVENTION; LETHAL DOSE; LIMIT OF DETECTION; MOUSE; NONHUMAN; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; SPLEEN CELL; SURVIVAL TIME; TH1 CELL; WESTERN BLOTTING;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL PROTEINS; CYTOKINES; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNITY, MUCOSAL; IMMUNOGLOBULINS; INTERLEUKIN-17; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; RECOMBINANT FUSION PROTEINS; STREPTOCOCCUS PNEUMONIAE;

EID: 84896475889     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.01391-13     Document Type: Article

References (50)

1. O'Brien KL, Wolfson LJ, Watt JP, Henkle E, Deloria-Knoll M, McCall N, Lee E, Mulholland K, Levine OS, Cherian T, Hib and Pneumococcal Global Burden of Disease Study Team. 2009. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 374:893-902. http://dx.doi.org/10.1016/S0140-6736(09) 61204-6.
2. Rodgers GL, Klugman KP. 2011. The future of pneumococcal disease prevention. Vaccine 29:C43-C48. http://dx.doi.org/10.1016/j.vaccine.2011.07.047.
3. Ginsburg AS, Nahm MH, Khambaty FM, Alderson MR. 2012. Issues and challenges in the development of pneumococcal protein vaccines. Expert Rev. Vaccines 11:279-285. http://dx.doi.org/10.1586/erv.12.5.
4. Jauneikaite E, Jefferies JM, Hibberd ML, Clarke SC. 2012. Prevalence of Streptococcus pneumoniae serotypes causing invasive and non-invasive disease in South East Asia: a review. Vaccine 30:3503-3514. http://dx.doi.org/10.1016/j.vaccine.2012.03.066.
5. Pitsiou GG, Kioumis IP. 2011. Pneumococcal vaccination in adults: does it really work? Respir. Med. 105:1776-1783. http://dx.doi.org/10.1016/j.rmed.2011.07.008.
6. Min X, Zhang X, Wang H, Gong Y, Li M, Xu W, Yin Y, Cao J. 2012. Protection against pneumococcal infection elicited by immunization with glutamyl tRNA synthetase, polyamine transport protein D and sortase A. Vaccine 30:3624-3633. http://dx.doi.org/10.1016/j.vaccine.2012.03.042.
7. Harfouche C, Filippini S, Gianfaldoni C, Ruggiero P, Moschioni M, Maccari S, Pancotto L, Arcidiacono L, Galletti B, Censini S, Mori E, Giuliani M, Facciotti C, Cartocci E, Savino S, Doro F, Pallaoro M, Nocadello S, Mancuso G, Haston M, Goldblatt D, Barocchi MA, Pizza M, Rappuoli R, Masignani V. 2012. RrgB321, a fusion protein of the three variants of the pneumococcal pilus backbone RrgB, is protective in vivo and elicits opsonic antibodies. Infect. Immun. 80:451-460. http://dx.doi.org/10.1128/IAI.05780-11.
8. Ogunniyi AD, Grabowicz M, Briles DE, Cook J, Paton JC. 2007. Development of a vaccine against invasive pneumococcal disease based on combinations of virulence proteins of Streptococcus pneumoniae. Infect. Immun. 75:350-357. http://dx.doi.org/10.1128/IAI.01103-06.
9. Cao J, Chen D, Xu W, Chen T, Xu S, Luo J, Zhao Q, Liu B, Wang D, Zhang X, Shan Y, Yin Y. 2007. Enhanced protection against pneumococcal infection elicited by immunization with the combination of PspA, PspC, and ClpP. Vaccine 25:4996-5005. http://dx.doi.org/10.1016/j.vaccine.2007.04.069.
10. Brandtzaeg P. 2010. Function of mucosa-associated lymphoid tissue in antibody formation. Immunol. Invest. 39:303-355. http://dx.doi.org/10.3109/08820131003680369.
11. Holmgren J, Czerkinsky C. 2005. Mucosal immunity and vaccines. Nature Med. 11:S45-S53. http://dx.doi.org/10.1038/nm1213.
12. Sheridan BS, Lefrancois L. 2011. Regional and mucosal memory T cells. Nat. Immunol. 12:485-491.
13. Lycke N. 2012. Recent progress in mucosal vaccine development: potential and limitations. Nat. Rev. Immunol. 12:592-605. http://dx.doi.org/10.1038/nri3251.
14. Bevan MJ. 2011. Memory T cells as an occupying force. Eur. J. Immunol. 41:1192-1195. http://dx.doi.org/10.1002/eji.201041377.
15. Mutsch M, Zhou W, Rhodes P, Bopp M, Chen RT, Linder T, Spyr C, Steffen R. 2004. Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. N. Engl. J. Med. 350:896-903. http://dx.doi.org/10.1056/NEJMoa030595.
16. Lewis DJ, Huo Z, Barnett S, Kromann I, Giemza R, Galiza E, Woodrow M, Thierry-Carstensen B, Andersen P, Novicki D, Del Giudice G, Rappuoli R. 2009. Transient facial nerve paralysis (Bell's palsy) following intranasal delivery of a genetically detoxified mutant of Escherichia coli heat labile toxin. PLoS One 4:e6999. http://dx.doi.org/10.1371/journal.pone.0006999.
17. Malley R, Henneke P, Morse SC, Cieslewicz MJ, Lipsitch M, Thompson CM, Kurt-Jones E, Paton JC, Wessels MR, Golenbock DT. 2003. Recognition of pneumolysin by Toll-like receptor 4 confers resistance to pneumococcal infection. Proc. Natl. Acad. Sci. U. S. A. 100:1966-1971. http://dx.doi.org/10.1073/pnas.0435928100.
18. Shoma S, Tsuchiya K, Kawamura I, Nomura T, Hara H, Uchiyama T, Daim S, Mitsuyama M. 2008. Critical involvement of pneumolysin in production of interleukin-1α and caspase-1-dependent cytokines in infection with Streptococcus pneumoniae in vitro: a novel function of pneumolysin in caspase-1 activation. Infect. Immun. 76:1547-1557. http://dx.doi.org/10.1128/IAI.01269-07.
19. Dogan S, Zhang Q, Pridmore AC, Mitchell TJ, Finn A, Murdoch C. 2011. Pneumolysin-induced CXCL8 production by nasopharyngeal epithelial cells is dependent on calcium flux and MAPK activation via Tolllike receptor 4. Microbes Infect. 13:65-75. http://dx.doi.org/10.1016/j.micinf.2010.10.003.
20. McNeela EA, Burke A, Neill DR, Baxter C, Fernandes VE, Ferreira D, Smeaton S, El-Rachkidy R, McLoughlin RM, Mori A, Moran B, Fitzgerald KA, Tschopp J, Petrilli V, Andrew PW, Kadioglu A, Lavelle EC. 2010. Pneumolysin activates the NLRP3 inflammasome and promotes proinflammatory cytokines independently of TLR4. PLoS Pathog. 6:e1001191. http://dx.doi.org/10.1371/journal.ppat.1001191.
21. Witzenrath M, Pache F, Lorenz D, Koppe U, Gutbier B, Tabeling C, Reppe K, Meixenberger K, Dorhoi A, Ma J, Holmes A, Trendelenburg G, Heimesaat MM, Bereswill S, van der Linden M, Tschopp J, Mitchell TJ, Suttorp N, Opitz B. 2011. The NLRP3 inflammasome is differentially activated by pneumolysin variants and contributes to host defense in pneumococcal pneumonia. J. Immunol. 187:434-440. http://dx.doi.org/10.4049/jimmunol.1003143.
22. Douce G, Ross K, Cowan G, Tao J, Tim M, Mitchell J. 2010. Novel mucosal vaccines generated by genetic conjugation of heterologous proteins to pneumolysin (PLY) from Streptococcus pneumoniae. Vaccine 28: 3231-3237. http://dx.doi.org/10.1016/j.vaccine.2010.02.014.
23. Simell B, Korkeila M, Pursiainen H, Kilpi TM, Käyhty H. 2001. Pneumococcal carriage and otitis media induce salivary antibodies to pneumococcal surface adhesin a, pneumolysin, and pneumococcal surface protein A in children. J. Infect. Dis. 183:887-896. http://dx.doi.org/10.1086/319246.
24. Holmlund E, Quiambao B, Ollgren J, Nohynek H, Käyhty H. 2006. Development of natural antibodies to pneumococcal surface protein A, pneumococcal surface adhesin A and pneumolysin in Filipino pregnant women and their infants in relation to pneumococcal carriage. Vaccine 24:57-65. http://dx.doi.org/10.1016/j.vaccine.2005.07.055.
25. Kirkham L-AS, Kerr AR, Douce GR, Paterson GK, Dilts DA, Liu D-F, Mitchell TJ. 2006. Construction and immunological characterization of a novel nontoxic protective pneumolysin mutant for use in future pneumococcal vaccines. Infect. Immun. 74:586-593. http://dx.doi.org/10.1128/IAI.74.1.586-593.2006.
26. Wu K, Zhang X, Shi J, Li N, Li D, Luo M, Cao J, Yin N, Wang H, Xu W, He Y, Yin Y. 2010. Immunization with a combination of three pneumococcal proteins confers additive and broad protection against Streptococcus pneumoniae infections in mice. Infect. Immun. 78:1276-1283. http://dx.doi.org/10.1128/IAI.00473-09.
27. Goulart C, da Silva TR, Rodriguez D, Politano WR, Leite LC, Darrieux M. 2013. Characterization of protective immune responses induced by pneumococcal surface protein A in fusion with pneumolysin derivatives. PLoS One 8:e59605. http://dx.doi.org/10.1371/journal.pone.0059605.
28. Lee C-J, Wang TR, Frasch CE. 2001. Immunogenicity in mice of pneumococcal glycoconjugate vaccines using pneumococcal protein carriers. Vaccine 19:3216-3225. http://dx.doi.org/10.1016/S0264-410X(01)00033-0.
29. Khan MN, Bansal A, Shukla D, Paliwal P, Sarada SK, Mustoori SR, Banerjee PK. 2006. Immunogenicity and protective efficacy of DnaJ (hsp40) of Streptococcus pneumoniae against lethal infection in mice. Vaccine 24:6225-6231. http://dx.doi.org/10.1016/j.vaccine.2006.05.074.
30. Cui Y, Zhang X, Gong Y, Niu S, Yin N, Yao R, Xu W, Li D, Wang H, He Y, Cao J, Yin Y. 2011. Immunization with DnaJ (hsp40) could elicit protection against nasopharyngeal colonization and invasive infection caused by different strains of Streptococcus pneumoniae. Vaccine 29:1736-1744. http://dx.doi.org/10.1016/j.vaccine.2010.12.126.
31. Cui J, Zhang Q, Dong J, Jiang H, Zhou A, Dong S, Zhang X, Yin Y, Hong W. 2011. Construction of DnaJ-deficient mutant strain of Streptococcus pneumoniae and its preliminary study on virulence. J. Third Mil. Med. Univ. 33:2000-2003.
32. Nakae S, Komiyama Y, Nambu A, Sudo K, Iwase M, Homma I, Sekikawa K, Asano M, Iwakura Y. 2002. Antigen-specific T cell sensitization is impaired in IL-17-deficient mice, causing suppression of allergic cellular and humoral responses. Immunity 17:375-387. http://dx.doi.org/10.1016/S1074-7613(02)00391-6.
33. Nguyen CT, Kim SY, Kim MS, Lee SE, Rhee JH. 2011. Intranasal immunization with recombinant PspA fused with a flagellin enhances cross-protective immunity against Streptococcus pneumoniae infection in mice. Vaccine 29:5731-5739. http://dx.doi.org/10.1016/j.vaccine.2011.05.095.
34. Gong Y, Xu W, Cui Y, Zhang X, Yao R, Li D, Wang H, He Y, Cao J, Yin Y. 2011. Immunization with a ZmpB-based protein vaccine could protect against pneumococcal diseases in mice. Infect. Immun. 79:867-878. http://dx.doi.org/10.1128/IAI.00717-10.
35. Cao J, Zhang X, Gong Y, Zhang Y, Cui Y, Lai X, Yin Y, Li M, Li D, Zhang L. 2013. Protection against pneumococcal infection elicited by immunization with multiple pneumococcal heat shock proteins. Vaccine 31:3564-3571. http://dx.doi.org/10.1016/j.vaccine.2013.05.061.
36. Lu Y-J, Gross J, Bogaert D, Finn A, Bagrade L, Zhang Q, Kolls JK, Srivastava A, Lundgren A, Forte S, Thompson CM, Harney KF, Anderson PW, Lipsitch M, Malley R. 2008. Interleukin-17A mediates acquired immunity to pneumococcal colonization. PLoS Pathog. 4:e1000159. http://dx.doi.org/10.1371/journal.ppat.1000159.
37. Moffitt KL, Gierahn TM, Lu YJ, Gouveia P, Alderson M, Flechtner JB, Higgins DE, Malley R. 2011. T(H)17-based vaccine design for prevention of Streptococcus pneumoniae colonization. Cell Host Microbe 9:158-165. http://dx.doi.org/10.1016/j.chom.2011.01.007.
38. Zhang Z, Clarke TB, Weiser JN. 2009. Cellular effectors mediating Th17-dependent clearance of pneumococcal colonization in mice. J. Clin. Invest. 119:1899-1909. http://dx.doi.org/10.1172/JCI36731.
39. Mowat AM, Donachie AM, Jägewall S, Schön K, Löwenadler B, Dalsgaard K, Kaastrup P, Lycke N. 2001. CTA1-DD-immune stimulating complexes: a novel, rationally designed combined mucosal vaccine adjuvant effective with nanogram doses of antigen. J. Immunol. 167:3398-3405. http://www.jimmunol.org/content/167/6/3398.long.
40. Peppoloni S, Ruggiero P, Contorni M, Morandi M, Pizza M, Rappuoli R, Podda A, Del Giudice G. 2003. Mutants of the Escherichia coli heatlabile enterotoxin as safe and strong adjuvants for intranasal delivery of vaccines. Expert Rev. Vaccines 2:285-293. http://dx.doi.org/10.1586/14760584.2.2.285.
41. Fujita Y, Taguchi H. 2012. Overview and outlook of Toll-like receptor ligand-antigen conjugate vaccines. Ther. Deliv. 3:749-760. http://dx.doi.org/10.4155/tde.12.52.
42. Turley CB, Rupp RE, Johnson C, Taylor DN, Wolfson J, Tussey L, Kavita U, Stanberry L, Shaw A. 2011. Safety and immunogenicity of a recombinant M2e-flagellin influenza vaccine (STF2.4xM2e) in healthy adults. Vaccine 29:5145-5152. http://dx.doi.org/10.1016/j.vaccine.2011.05.041.
43. Treanor JJ, Taylor DN, Tussey L, Hay C, Nolan C, Fitzgerald T, Liu G, Kavita U, Song L, Dark I, Shaw A. 2010. Safety and immunogenicity of a recombinant hemagglutinin influenza-flagellin fusion vaccine (VAX125) in healthy young adults. Vaccine 28:8268-8274. http://dx.doi.org/10.1016/j.vaccine.2010.10.009.
44. Dessing MC, Hirst RA, de Vos AF, van der Poll T. 2009. Role of Toll-like receptors 2 and 4 in pulmonary inflammation and injury induced by pneumolysin in mice. PLoS One 4:e7993. http://dx.doi.org/10.1371/journal.pone.0007993.
45. Mestecky J, Russell MW, Elson CO. 1999. Intestinal IgA: novel views on its function in the defence of the largest mucosal surface. Gut 44:2-5. http://dx.doi.org/10.1136/gut.44.1.2.
46. Wild J, Rossmeissl P, Walter WA, Gross CA. 1996. Involvement of the DnaK-DnaJ-GrpE chaperone team in protein secretion in Escherichia coli. J. Bacteriol. 178:3608-3613.
47. Lundgren A, Bhuiyan TR, Novak D, Kaim J, Reske A, Lu Y-J, Qadri F, Malley R. 2012. Characterization of Th17 responses to Streptococcus pneumoniae in humans: comparisons between adults and children in a developed and a developing country. Vaccine 30:3897-3907. http://dx.doi.org/10.1016/j.vaccine.2012.03.082.
48. Jahn-Schmid B, Messner P, Unger FM, Sleytr UB, Scheiner O, Kraft D. 1996. Toward selective elicitation of TH1-controlled vaccination responses: vaccine applications of bacterial surface layer proteins. J. Biotechnol. 44:225-231. http://dx.doi.org/10.1016/0168-1656(95)00124-7.
49. Hirota K, Turner J-E, Villa M, Duarte JH, Demengeot J, Steinmetz OM, Stockinger B. 2013. Plasticity of TH17 cells in Peyer's patches is responsible for the induction of T cell-dependent IgA responses. Nat. Immunol. 14:372-379. http://dx.doi.org/10.1038/ni.2552.
50. Jaffar Z, Ferrini ME, Herritt LA, Roberts K. 2009. Cutting edge: lung mucosal Th17-mediated responses induce polymeric Ig receptor expression by the airway epithelium and elevate secretory IgA levels. J. Immunol. 182:4507-4511. http://dx.doi.org/10.4049/jimmunol.0900237